Christopher Coppola
Family Medicine · Vero Beach, FLNPI 1003803909
Payments from drug & device makers
Across 120 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$430
- Pfizer$245
- Novo Nordisk$206
- Novartis$195
- Boehringer Ingelheim$177
- Bayer$121
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,39797%
- Education$663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $430 |
| Pfizer | 13 | $245 |
| Novo Nordisk | 11 | $206 |
| Novartis | 11 | $195 |
| Boehringer Ingelheim | 9 | $177 |
| Bayer | 6 | $121 |
| Amgen | 7 | $119 |
| Medtronic(2 entities) | 2 | $116 |
| AstraZeneca | 6 | $114 |
| Astellas Pharma US Inc | 3 | $101 |
| Amarin Pharma, Inc. | 5 | $97 |
| AbbVie(2 entities) | 5 | $91 |
| Johnson & Johnson | 4 | $74 |
| Insmed, Inc. | 2 | $57 |
| Exact Sciences | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Merck | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Abbott | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Biogen | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$101
How this compares
$2,463 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $50,744 |
| EliquisApixaban | 47 | $49,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $27,654 |
| TrulicityDulaglutide | 13 | $19,239 |
| JardianceEmpagliflozin | 13 | $16,539 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 30 | $8,485 |
| Levothyroxine Sodium | 379 | $6,360 |
| Atorvastatin Calcium | 443 | $5,367 |
| Gabapentin | 113 | $5,212 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $4,258 |
| Pantoprazole Sodium | 127 | $3,183 |
| Buspirone Hcl | 51 | $3,065 |
| Rosuvastatin Calcium | 154 | $2,429 |
| Duloxetine Hcl | 37 | $2,427 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $206 | $50,74439 claims |
| PfizerEliquis | $245 | $49,38947 claims |
| GSKTrelegy Ellipta | $430 | $27,65425 claims |
| Lilly USA, LLCTrulicity | $21 | $19,23913 claims |
| Boehringer IngelheimJardiance | $177 | $16,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Vero Beach
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.